3 Under-the-Radar Biotech Stocks You Need to Watch in 2014
Nektar Therapeutics, Omeros, and Spectrum Pharmaceuticals all face off with regulators in key decision dates for their developmental drugs later this year
Is Spectrum Pharmaceuticals, Inc. Blazing the Comeback Trail?
Spectrum Pharmaceuticals has been one of the rare losers in the biopharma sector. That trend may be set to change, however, as the company has set itself up for long-term growth.